Binimetinib — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

5 Recruiting

9 Completed trials

10 Sponsors

16 Countries

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 9 Phase IV: 2 Phase I (FiH): 1

Indications tested

Metastatic malignant melanoma 2 Malignant melanoma 2 Melanoma recurrent 2 Malignant melanoma stage IV 2 Central nervous system melanoma 2 Malignant melanoma stage III 2 BRAF V600E mutation positive 1 Colorectal cancer metastatic 1 Non-small cell lung cancer stage IV 1 Colorectal adenocarcinoma 1 Non-small cell lung cancer 1

Sponsors using this IMP

Pfizer Inc. 4 Unicancer 2 Asociacion Grupo Tratamiento De Tumores Digestivos 1 European Organisation For Research And Treatment Of Cancer 1 Grupo Espanol Multidisciplinar De Melanoma 1 Intergroupe Francophone De Cancerologie Thoracique 1 Oslo University Hospital HF 1 Region Hovedstaden 1 SRH Wald-Klinikum Gera GmbH 1 Universitair Medisch Centrum Utrecht 1

All trials

14 total

Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim… Recruiting

2024-513375-40-00 Phase II 1 country Grupo Espanol Multidisciplinar De Melanoma
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Phase III 2 countries Unicancer
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction tre… Recruiting

2022-502413-29-00 Phase II 1 country Asociacion Grupo Tratamiento De Tumores Digestivos
EVIDENT Recruiting

2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial Recruiting

2024-516585-11-00 Phase II 1 country Region Hovedstaden
Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended

2023-509408-13-00 Phase IV 9 countries Pfizer Inc.
Binimetinib, Encorafenib and Pembrolizumab COmbination in MElanoma - Metastatic to the Brain Ended

2023-505302-42-00 Phase II 1 country Unicancer
The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended

2024-512038-13-00 Phase III 11 countries Pfizer Inc.
Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended

2024-515944-22-00 Phase II 1 country Intergroupe Francophone De Cancerologie Thoracique
Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended

2023-505376-30-00 Phase II 6 countries European Organisation For Research And Treatment Of Cancer
Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended

2023-509471-17-00 Phase II 5 countries Pfizer Inc.
A dose-esalation phase I/II study in patients with RAS-mutated metastatic colorectal cancer to investigate safety and clinical actvitiy of t… Ended

2023-509732-25-00 Phase I (FiH) 1 country Universitair Medisch Centrum Utrecht
A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer. Ended

2024-515929-28-00 Phase II 3 countries Pfizer Inc.
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melan… Ended

2024-516073-74-00 Phase IV 1 country SRH Wald-Klinikum Gera GmbH

Showing 1–14 of 14 trials

← All drugs A–Z